Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025
Achilles Therapeutics Q4 EPS $(0.46) May Not Be Comparable To $(0.14) Estimate, Cash Position Of $131.5M Supports Operations Through 2025
Achilles Therapeutics第四季度每股收益美元（0.46美元）可能无法与估计的0.14美元（0.14美元）相提并论，1.315亿美元的现金状况支持2025年之前的运营
Achilles Therapeutics (NASDAQ:ACHL) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.14) by 228.57 percent. This is a 24.59 percent increase over losses of $(0.61) per share from the same period last year.
Achilles Therapeutics（纳斯达克股票代码：ACHL）公布的季度亏损为每股0.46美元，比分析师普遍预期的0.14美元（0.14美元）低228.57％。与去年同期每股亏损0.61美元（0.61美元）相比，增长了24.59％。